|
SEARCH | SUBSCRIBE | ||
US drops Brazil, Aids drug case
The United
States has dropped its complaint against Brazil for allowing the
production of generic Aids-treatment drugs within the South American
country. The Bush
administration made the announcement as a three-day special United Nations
session on HIV/Aids was getting underway in New York. Thousands of
patients are expected to benefit from the move. Trade
Representative Robert Zoellick said the US and Brazil had established a
new mechanism to address the dispute, which centers on where certain Aids
drugs will be manufactured. "The
Bush administration wants to resolve trade disputes by seeking
constructive solutions to problems that arise," Mr Zoellick said. "With
this positive step, we will be able to harness our common energy toward
our shared goal of combating the spread of this dangerous virus," he
said. Protectionist
measure The US filed
its complaint with the World Trade Organisation (WTO) in February over a
Brazilian law that permits a local company to manufacture a product, made
by a foreign company, if that company fails to initiate production within
Brazil within three years. The US
complained that the Brazilian law discriminated against all imported
products and was a protectionist measure. For its part,
Brazil had accused the Bush administration of launching an attack on its
successful Aids-treatment programme, adding that the pharmaceutical
industry exerts a disproportionate influence on Washington. Brazil has
said its law permitting production of generic drugs was an "important
instrument" in battling HIV/Aids. It has halved annual deaths from
the disease since 1995, thanks to free distribution of mainly
Brazilian-produced Aids drugs. Brazilian
president Fernando Henrique Cardoso has vigorously defended his country's
practice of ignoring patents on anti-Aids drugs. Free treatment The charity
Medicins Sans Frontieres says the Brazilian Government's programme has
allowed it to offer free treatment to more than 90,000 patients. The group
said the programme would be threatened if Brazil had to pay higher prices
for imported drugs. It is not the first time the US has come under fire over its objection to the production of generic Aids drugs. The US in
recent years has come under much scrutiny for supporting the intellectual
property rights of US drug manufacturers who do not want foreign countries
manufacturing cheaper generic equivalents. Most of the
controversy has focused on Africa, where even generic drugs are beyond the
financial means of those suffering from HIV/Aids. In April, the
United Nations Human Rights Commission voted overwhelmingly to support a
Brazilian resolution calling for universal medical treatment for people
with HIV and Aids. The UN says
Aids has killed 22 million people and orphaned 13 million children. The
global infection rate is now 15,000 people a day, 5 million a year, and 36
million are living with the virus. |